Lutein ( DrugBank: Lutein )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| 90 | Retinitis pigmentosa | 2 |
| 164 | Oculocutaneous albinism | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04843813 (ClinicalTrials.gov) | March 26, 2021 | 7/4/2021 | Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients- | Lutein and Multiple Sclerosis Experimental Study (LuMES) | Multiple Sclerosis | Dietary Supplement: Lutein;Dietary Supplement: Placebo | University of Illinois at Urbana-Champaign | Division of Nutritional Sciences, University of Illinois at Urbana-Champaign;National Institutes of Health Rehabilitation Research Resource to Enhance Clinical Trials (REACT) | Recruiting | 18 Years | 64 Years | All | 60 | N/A | United States |
90. Retinitis pigmentosa
Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00346333 (ClinicalTrials.gov) | July 2003 | 27/6/2006 | Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A | Randomized Clinical Trial for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Lutein;Dietary Supplement: Cornstarch control | National Eye Institute (NEI) | NULL | Completed | 18 Years | 60 Years | All | 240 | Phase 3 | United States |
| 2 | NCT00029289 (ClinicalTrials.gov) | April 2001 | 9/1/2002 | Effects of Lutein in Retinitis Pigmentosa | Effects of Lutein in Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Lutein (10 or 30 mg/day) capsules | National Center for Complementary and Integrative Health (NCCIH) | NULL | Completed | Phase 1/Phase 2 | United States |
164. Oculocutaneous albinism
Clinical trials : 15 / Drugs : 57 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02200263 (ClinicalTrials.gov) | November 2014 | 23/7/2014 | The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism | A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA) | Ocular Albinism (OA);Oculocutaneous Albinism (OCA) | Dietary Supplement: Lutein plus Zeaxanthin;Dietary Supplement: Placebo | Johns Hopkins University | Clark Charitable Foundation Inc. | Completed | 12 Years | N/A | All | 10 | N/A | United States |